What's new? Log in Free sign up

argenx SE (ARGX)

Company Profile

Company profile

Ticker

ARGX

Exchange

Website

CEO

Mr. Timothy Van Hauwermeiren EMBA, M.Sc.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Kite Realty Group Trust • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics ...

Former names

argenx N.V

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

ARGX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$708.33

Low target

$696.00

High target

$723.00

Market Outperform

Evercore ISI Group

Latest filings (excl ownership)

View all

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP

Current report (foreign)

First and only NMPA-approved treatment for patients with CIDP in China

CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

PRICE T ROWE ASSOCIATES INC /MD/

PRICE T ROWE ASSOCIATES INC /MD/

Artisan Partners Limited Partnership

PRICE T ROWE ASSOCIATES INC /MD/

Artisan Partners Limited Partnership

Financial summary

Financial statements Chart ARGX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from argenx SE earnings reports.

Institutional ownership, Q3 2024

ARGX institutional ownership history Ownership history

57.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	356	335	+6.3%
Opened positions	54	61	-11.5%
Closed positions	33	43	-23.3%
Increased positions	134	125	+7.2%
Reduced positions	114	102	+11.8%

13F shares	Current	Prev Q	Change
Total value	15.13 tn	11.30 tn	+33.8%
Total shares	35.03 mm	34.26 mm	+2.2%
Total puts	489.40 k	429.00 k	+14.1%
Total calls	375.40 k	302.30 k	+24.2%
Total put/call ratio	1.3	1.4	-8.1%

Largest owners	Shares	Value	Change
T. Rowe Price	5.82 mm	$3.16 bn	+4.0%
FMR	4.79 mm	$2.60 tn	+35.9%
Artisan Partners Limited Partnership	3.51 mm	$1.90 tn	+0.1%
JHG Janus Henderson	2.48 mm	$1.34 tn	+0.4%
Capital World Investors	1.70 mm	$921.63 bn	+12.5%
Avoro Capital Advisors	1.24 mm	$671.35 bn	0.0%
BlackRock	1.12 mm	$609.74 bn	NEW
MS Morgan Stanley	930.75 k	$504.54 bn	+13.5%
T. Rowe Price Investment Management	771.57 k	$418.25 mm	-59.9%
RTW Investments	654.43 k	$354.75 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
FMR	4.79 mm	+1.27 mm	+35.9%
T. Rowe Price Investment Management	771.57 k	-1.15 mm	-59.9%
BlackRock	1.12 mm	+1.12 mm	NEW
BLK BlackRock	0.00	-1.01 mm	EXIT
IVZ Invesco	433.52 k	+232.04 k	+115.2%
Holocene Advisors	195.10 k	-230.51 k	-54.2%
T. Rowe Price	5.82 mm	+221.98 k	+4.0%
Capital World Investors	1.70 mm	+188.76 k	+12.5%
Lord, Abbett & Co.	162.96 k	+162.96 k	NEW
JEF Jefferies Financial	160.00 k	+159.95 k	+319900.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

HC Wainwright & Co. Reiterates Buy on argenx, Raises Price Target to $717

HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and raises the price target from $670 to $717.

Truist Securities Reiterates Buy on argenx, Raises Price Target to $700

JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $696

Press releases

From Benzinga Pro

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.